sC5b-9 Antibody (Monoclonal - neoantigen)
A murine monoclonal antibody to a neoantigen on the terminal complement complex.
Product Specifications
Citations | 27 |
---|---|
Clonality |
Monoclonal |
Immunogen | Purified human protein. |
Applications | See citations and technical data sheet for application info. |
Concentration | 1.0-1.2 mg/mL |
Conjugate | Unconjugated |
Cross Reactivity |
Human, Baboon, Cynomologus macaque, Rhesus macaque. |
Ordering Information
Catalog Number | A239 |
---|---|
Catalog Number (CE) | N/A |
Size | 100 µl |
Price (USD) | $365.00 |
Price (EURO) | 330,00 € |
Contact us
US Phone | +1 (858) 552 1100 |
---|---|
EU Phone | +353 (91) 412 474 |
US Email | contact-us@quidelortho.com |
EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
Description |
A murine monoclonal antibody to a neoantigen on the terminal complement complex. |
---|---|
Size | 100 µl |
Concentration |
1.0-1.2 mg/mL |
Applications | See citations and technical data sheet for application info. |
Form | Liquid. Borate Buffered Saline (pH 8.4 ± 0.2), with ≤ 0.1% Sodium Azide. |
Clonality | Monoclonal |
Immunogen | Purified human protein. |
Conjugate | Unconjugated |
Cross Reactivity | Human, Baboon, Cynomologus macaque, Rhesus macaque. |
Isotype | IgG2bk |
Purity | ≥ 95% by SDS PAGE |
Source |
Mouse |
Specificity | This monoclonal antibody was raised against purified human C9. This antibody has been shown to bind to a neoantigen expressed on SC5b-9, TCC, MAC, poly- C9 and on denatured immobilized C9. |
Storage |
Short term (30 days) 4˚C. Long term at or below –20˚C. |
Background |
The Terminal Complement Complex (TCC, SC5b-9) is generated by the assembly of C5 through C9 as a consequence of activation of the complement system by either the classical, lectin or alternative pathway. The membrane attack complex (MAC), a form of TCC, is a stable complex that mediates the irreversible target cell membrane damage associated with complement activation. Complexes formed in the absence of a target membrane bind to naturally occurring regulatory serum proteins, e.g. the S protein, at the C5b-7 stage of assembly forming soluble, non-lytic TCC. |
Citations
Title | Year | Applications | Sample Species | Sample | Sample Details |
---|---|---|---|---|---|
2013 | IF |
Bacteria |
Borrelia valaisiana |
||
CspA from Borrelia burgdorferi inhibits the terminal complement pathway. |
2013 | IF |
Bacteria |
Borrelia burgdorferi |
|
EGFR modulates complement activation in head and neck squamous cell carcinoma. |
2020 | IF |
Cell Culture |
HNSCC Cells |
|
2016 | IF, WB |
Cell Culture |
Plasmodium falciparum culture |
||
2021 | Complement Activation Assay, WB |
Human |
Serum |
||
2018 | ELISA |
Human |
Serum |
||
Establishing a Case for Anti-complement Therapy in Membranous Nephropathy. |
2020 | ELISA |
Human |
Urine |
Membranous Nephropathy |
The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare. |
2021 | ELISA |
Human |
Plasma |
Lupus Nephritis |
Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients. |
2021 | ELISA |
Human |
Plasma |
|
Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney. |
2022 | ELISA |
Human |
Plasma |
Antibody Mediated Rejection |
2022 | ELISA |
Human |
Serum |
CipA |
|
2009 | ELISA |
Human |
Plasma |
||
2018 | ELISA |
Human |
Serum |
||
Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. |
1998 | ELISA |
Human |
Amyloid-βeta peptides & NHS |
|
High-Mobility Group Box 1-Induced Complement Activation Causes Sterile Inflammation. |
2018 | ELISA, IF |
Human |
Serum |
HMGB1-coated microplates |
2008 | IF |
Human |
Placenta Tissue |
||
2015 | IF |
Human |
Skin Tissue |
||
2016 | IF, WB |
Human |
Red Blood Cells |
Plasmodium falciparum incubated |
|
Terminal complement complex formation is associated with intervertebral disc degeneration. |
2020 | IHC |
Human |
Spinal Cord Tissue |
|
2021 | IHC |
Human |
Disc Tissue |
||
2021 | IHC |
Human |
Placenta Tissue |
||
Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy |
2015 | IHC |
Human |
Kidney Tissue |
Thrombotic Microangiopathy |
2005 | Radiation Immunoassay |
Human |
Serum |
Haemophilus ducreyi incubated |
|
2006 | WB |
Human |
Serum |
Moraxella catarrhalis |
|
2015 | FC |
Porcine |
Articular chondrocytes |
||
2008 | FC, IF |
Rat |
Spinal Cord Tissue |
||
2005 | IHC |
Rhesus Monkey |
Brain Tissue |